Investigational drug · Phase 2
HRS-1167
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "HRS-1167"
First trial start
2024
Sep 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-1167", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-1167" as an intervention, largest first.
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05473624 · 153 participants (planned) · Start Aug 23, 2022 · Primary completion Dec 31, 2026
Drug: HRS-1167 · For: Advanced Solid Tumors
Sites: Beijing, China; Chongqing, China; Nanning, China · 20 sites in all
Fudan UniversityAcademic, hospital or other
NCT06516289 · 130 participants (planned) · Start Sep 30, 2024 · Primary completion Jun 2026
Drug: HRS-1167; Famitinib and 1 more · For: BRCA-Mutated Breast Carcinoma; HER2-negative Breast Cancer
Sites: Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06568094 · 100 participants (planned) · Start Sep 25, 2024 · Primary completion Dec 2026
Drug: HRS-5041 tablets; Abiraterone Acetate tablets(II) and 6 more · For: Prostate Cancer
Sites: Harbin, China; Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06689163 · 66 participants (planned) · Start Dec 11, 2024 · Primary completion Nov 30, 2025
Drug: HRS-1167 tablets; Abiraterone Acetate tablets(II) and 1 more · For: Prostate Cancer
Sites: Hefei, China; Changsha, China
- M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT06421935 · 60 participants · Start Aug 7, 2024 · Primary completion Feb 22, 2027
Drug: M9466; Tuvusertib and 2 more · For: Advanced Solid Tumor
Sites: New York, New York; Houston, Texas; Adelaide, Australia · 20 sites in all
- A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian CancerStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06308406 · 54 participants (planned) · Start Mar 15, 2024 · Primary completion Oct 2025
Drug: Bevacizumab; HRS-1167 · For: Recurrent Ovarian Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 18 sites in all
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06198556 · 18 participants · Start Jan 14, 2024 · Primary completion Feb 5, 2024
Drug: HRS-1167 tablets; rifampicin · For: Advanced Solid Tumor
Sites: Guangzhou, China
EMD Serono Research & Development Institute, Inc.Industry
NCT06509906 · 3 participants · Start Oct 8, 2024 · Primary completion Dec 2, 2025
Drug: M9466; Irinotecan and 4 more · For: Advanced Solid Tumor
Sites: Denver, Colorado; Pennington, New Jersey; Nashville, Tennessee · 12 sites in all
- Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)Withdrawn
EMD Serono Research & Development Institute, Inc.Industry
NCT06719973 · 0 participants · Start May 14, 2025 · Primary completion May 14, 2025
Drug: M9466; Carboplatin and 5 more · For: Advanced Solid Tumors
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.